Results 51 to 60 of about 104,562 (257)
Warfarin therapy and pharmacogenetics: A narrative review of regional and Iraqi studies
Medical Journal of Babylon, 2022 The aim of this work was to review several studies investigating the effects of genetic polymorphisms on warfarin dosing in regional and Iraqi studies and to report any consistent pattern of relevant findings.
Ali Mohammed Abd Alridha +2 more
doaj +1 more source
Is home warfarin self-management effective? Results of the Randomised Self-Management of Anticoagulation Research Trial [PDF]
, 2013 Aims The Warfarin Self-Management Anticoagulation Research Trial (Warfarin SMART) was designed to determine whether patients self-managing warfarin (PSM) using the CoaguChek device and a dosing algorithm developed for the trial could keep the INR ...
Gebski, Val +5 more
core
Warfarin Resisance and Recurrent Thrombosis in an Iranian Patient
Case Reports in Clinical Practice, 2019 Warfarin resisance was known as subtherapeutic INR (International Normalized Ratio) in spite of normally prescribed doses of warfarin. There are few reports of warfarin resisance from Iran.
Masuod Malekzadeh, Marzieh Pazoki
doaj
Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model
ADMET and DMPK, 2021 Background: Pharmacokinetics of warfarin has not been described in our population. We derived the pharmacokinetic parameters from a validated pharmacokinetic-pharmacodynamic model. Methods: Patients receiving warfarin for at least 6 months were recruited
Kannan Sridharan +2 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Real‐world evidence (RWE) derived from real‐world data (RWD) can complement randomized controlled trials (RCTs), yet the validity of RWD relative to RCT data remains insufficiently characterized. We obtained post hoc consent and linked individual participant data from the US‐based INVESTED trial (2016–2019) with Medicare fee‐for‐service claims (2012 ...
Hanseul Cho +12 more
wiley +1 more source
BMC Cardiovascular Disorders, 2019 Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among patients with non-valvular atrial fibrillation (NVAF), but the ...
Kiran Gupta +7 more
doaj +1 more source
BMC Research Notes, 2023 Objective To study the profile, clinical presentation and outcome of hospital stay among patients admitted with warfarin toxicity at the Jigme Dorji Wangchuck National Referral Hospital, Bhutan.
Yeshey Penjore +3 more
doaj +1 more source
No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke [PDF]
, 2012 Background: Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-to-benefit profile of DE compared to warfarin. In this study, we evaluated whether hemorrhagic transformation (HT) occurs after
Ferdinand Bohmann +27 more
core +2 more sources
Clinical Pharmacology &Therapeutics, EarlyView.The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang +5 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Almost half of individuals with hypertension fail to achieve recommended blood pressure (BP) goals. Pharmacogenetic gene‐drug interactions may alter the efficacy of antihypertensive agents. We conducted a multicenter randomized controlled sub‐study of participants (N = 1874) with hypertension and self‐reported African ancestry to determine whether ...
Philip E. Empey +25 more
wiley +1 more source